epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2020-19-6-79-85epidemiology-1123Research ArticleОБЗОРREVIEWКлинические и иммунологические аспекты пневмококковой вакцинации у пациентов с множественной миеломойClinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myelomahttps://orcid.org/0000-0003-0483-7329СтомаИ. О.StomaI. O.

Стома Игорь Олегович – доктор медицинских наук, доцент, ректор ГомГМУ.246000, Гомель, ул. Ланге, 5.Тел. +375 (232) 35-98-18

Stoma Igor Olegovich - Dr. Sci. (Med.), Associate Professor, Chancellor of educational institution «Gomel state medical university».246000, Gomel, Lange str., 5.Tel. +375 (232) 35-98-18

igor.stoma@gmail.comГомельский государственный медицинский университетБеларусьGomel state medical universityBelarus2020130120211967985Copyright © Стома И.О., 20212021Стома И.О.Stoma I.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1123

Актуальность. Среди групп высокого риска развития инвазивных пневмококковых инфекций пациенты с множественной миеломой (ММ) выделяются одними из самых высоких показателей первичной заболеваемости и летальности по причине наличия глубокой иммуносупрессии. Цель: обозначить современное состояние проблемы вакцинопрофилактики пневмококковой инфекции у пациентов, получающих лечение по поводу множественной миеломы, обосновать доказательную базу вакцинации коньюгированной пневомококковой вакциной. В работе применялся метод сплошного обзора данных в отношении исследований на тему вакцинации против пневмококковой инфекции у пациентов с множественной миеломой. Выводы. В статье представлены современные эпидемиологические данные, а также результаты оригинальных исследований клинических и иммунологических аспектов пневмококковой вакцинации у пациентов с ММ, получающих новые таргетные агенты и иммунопрепараты. Обозначена эффективность применения коньюгированной пневмококковой вакцины у пациентов на фоне лечения ММ бор-тезомибом, леналидомидом, иксазомибом. Показано независимое защитное влияние пневмококковой вакцинации как меры профилактического воздействия в когорте пациентов с ММ на фоне лечения новыми таргетными лекарственными средствами.

Relevance. Among the groups at high risk of developing invasive pneumococcal infections, patients with multiple myeloma (MM) stand out among the highest rates of morbidity and mortality due to the presence of profound immunosuppression. Aims: to outline the current state of the problem of vaccine prevention of pneumococcal infection in patients receiving treatment for multiple myeloma, to present the evidence base for vaccination with conjugated pneumococcal vaccine. A continuous data review method was used to evaluate the studies on vaccination approaches against pneumococcal infection in patients with multiple myeloma. Conclusions. The article presents modern epidemiological data, as well as the results of original studies of clinical and immunological aspects of pneumococcal vaccination in patients with MM receiving new targeted agents and immunotherapy. The effectiveness of the use of the conjugated pneumococcal vaccine in patients treated with MM with bortezomib, lenalidomide, and ixazomib was indicated. An independent protective effect of pneumococcal vaccination has been shown as a preventive measure in a cohort of patients with MM, against the background of treatment with new targeted drugs.

пневмококковая инфекциявакцинациямножественная миеломапневмониятрансплантацияpneumococcal infectionvaccinationmultiple myelomapneumoniatransplantationreviewСтатья подготовлена при финансовой поддержке компании Пфайзер.Pfizer provided financial support the development of the manuscript.ReferencesKamboj, M, Shah, MK. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infectious Disease Clinics of North America. 2019;33(2):593-609.Kamboj, M, Shah, MK. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infectious Disease Clinics of North America. 2019;33(2):593-609.Meroni, PL. Zavaglia, D, Girmenia, C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clinical and Experimental Rheumatology. 2018;36(2):317-328.Meroni, PL. Zavaglia, D, Girmenia, C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clinical and Experimental Rheumatology. 2018;36(2):317-328.Monier, A, Puyade M., Gallego Hernanz MP, et al. Observational study of vaccination in cancer patients: How can vaccine coverage be improved? Medecine Et Maladies Infectieuses. 2020;50(3); 263-268. D0l:10.1016/j.medmal.2019.11.006Monier, A, Puyade M., Gallego Hernanz MP, et al. Observational study of vaccination in cancer patients: How can vaccine coverage be improved? Medecine Et Maladies Infectieuses. 2020;50(3); 263-268. D0l:10.1016/j.medmal.2019.11.006Klu gman, KP, Madhi, SA, Feldman, C. HIV and pneumococcal disease. Current opinion in infectious diseases. 2007(20)1:11-15.Klu gman, KP, Madhi, SA, Feldman, C. HIV and pneumococcal disease. Current opinion in infectious diseases. 2007(20)1:11-15.Shatz, DV. Vaccination considerations in the asplenic patient. Expert review of vaccines. - 2005;4(1):27-34.Shatz, DV. Vaccination considerations in the asplenic patient. Expert review of vaccines. - 2005;4(1):27-34.Augustson, BM, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(36):9219-9226.Augustson, BM, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(36):9219-9226.Blimark, C, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(10):107-113.Blimark, C, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(10):107-113.Hallam, S. TEAMM Work Saves Lives in Myeloma. HemaSphere. 2018;2(1):E24.Hallam, S. TEAMM Work Saves Lives in Myeloma. HemaSphere. 2018;2(1):E24.Zarco-Marquez, S, et al. Invasive and complicated pneumococcal infection in patients with cancer. Revista De Investigation Clinica; Organo Del Hospital De Enfermedades De La Nutricion. 2016;68(5):221-228.Zarco-Marquez, S, et al. Invasive and complicated pneumococcal infection in patients with cancer. Revista De Investigation Clinica; Organo Del Hospital De Enfermedades De La Nutricion. 2016;68(5):221-228.Chong, PP, Avery, RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clinical Therapeutics. 2017; 39(8):1581-1598.Chong, PP, Avery, RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clinical Therapeutics. 2017; 39(8):1581-1598.Langedijk, AC, et al. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine. 2019;37(3):510-515.Langedijk, AC, et al. Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine. 2019;37(3):510-515.Palazzo, M, et al. Revaccination after Autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018;24(4):871-876.Palazzo, M, et al. Revaccination after Autologous hematopoietic stem cell transplantation is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2018;24(4):871-876.Cordonnier, C, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28(15):2730-2734.Cordonnier, C, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28(15):2730-2734.Cordonnier, C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >2 years: an open-label study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015;61(3):313-323.Cordonnier, C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >2 years: an open-label study. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015;61(3):313-323.Tsigrelis, C, Ljungman, P. Vaccinations in patients with hematological malignancies. Blood Reviews. 2016;30(2)139-147.Tsigrelis, C, Ljungman, P. Vaccinations in patients with hematological malignancies. Blood Reviews. 2016;30(2)139-147.Cordonnier, C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet. Infectious Diseases. 2019;19(6):E200-e212.Cordonnier, C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet. Infectious Diseases. 2019;19(6):E200-e212.Westerink, MAJ, Schroeder, HW, Nahm, MH. Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging and Disease. 2012;3(1):17.Westerink, MAJ, Schroeder, HW, Nahm, MH. Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging and Disease. 2012;3(1):17.Black, SB, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. The Pediatric Infectious Disease Journal. 1991;10(2):97-104.Black, SB, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. The Pediatric Infectious Disease Journal. 1991;10(2):97-104.Stein, KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. The Journal of Infectious Diseases. 1992;165(1):S49-52.Stein, KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. The Journal of Infectious Diseases. 1992;165(1):S49-52.Kayhty, H, Eskola, J. New vaccines for the prevention of pneumococcal infections. Emerging Infectious Diseases. 1996;2(4):289-298.Kayhty, H, Eskola, J. New vaccines for the prevention of pneumococcal infections. Emerging Infectious Diseases. 1996;2(4):289-298.Mccool, TL et al. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. INFECT. IMMUN. 1999;67:8.Mccool, TL et al. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. INFECT. IMMUN. 1999;67:8.Pletz, MW, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents. 2008;32(3):199-206.Pletz, MW, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents. 2008;32(3):199-206.Jochems, SP, et al. The immunological mechanisms that control pneumococcal carriage. PLoS pathogens. 2017;13(12):E1006665.Jochems, SP, et al. The immunological mechanisms that control pneumococcal carriage. PLoS pathogens. 2017;13(12):E1006665.Иммунологическое обоснование сроков вакцинопрофилактики пневмококковой инфекции у пациентов с множественной миеломой после аутологичной трансплантации гемопоэтических стволовых клеток [Электронный ресурс]. 2020. Режим доступа: https://medmag.bsmu.by/category68/article2983/. Дата доступа: 08.05.2020.Immunological substantiation of the timing of vaccine prevention of pneumococcal infection in patients with multiple myeloma after autologous hematopoietic stem cell transplantation [Electronic resource]. 2020. Access mode: https://medmag.bsmu.by/category68/article2983/. Access date: 05/08/2020.Stoma, I, et al. Immunological reconstitution as a basis for the early initiation of pneumococcal vaccination after autologous hematopoietic stem cell transplantation. HemaSphere. 2019;3:342-343. -. DOI: 10.1097/01.HS9.0000561392.22749.84.Stoma, I, et al. Immunological reconstitution as a basis for the early initiation of pneumococcal vaccination after autologous hematopoietic stem cell transplantation. HemaSphere. 2019;3:342-343. -. DOI: 10.1097/01.HS9.0000561392.22749.84.French, N, et al. A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine. 2010;362(9):812-822.French, N, et al. A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine. 2010;362(9):812-822.Crum-Cianflone, NF, Wallace, MR. Vaccination in HIV-Infected Adults. AIDS Patient Care and STDs. 2014;28(8):397-410.Crum-Cianflone, NF, Wallace, MR. Vaccination in HIV-Infected Adults. AIDS Patient Care and STDs. 2014;28(8):397-410.Gong, J, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer. 2018;6(1):8.Gong, J, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for Immunotherapy of Cancer. 2018;6(1):8.Gajewski, TF, Schreiber, H, Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 2013;14(10):1014-1022.Gajewski, TF, Schreiber, H, Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 2013;14(10):1014-1022.Altmann, DM. A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology. 2018;155(3):283-284.Altmann, DM. A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology. 2018;155(3):283-284.Chim, CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262.Chim, CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262.Ludwig, H, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542-1560.Ludwig, H, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542-1560.Gay, F, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197-211.Gay, F, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197-211.Ludwig, H, Zojer, N. Supportive care in multiple myeloma. Best Practice & Research. Clinical Haematology. 2007;20(4):817-835.Ludwig, H, Zojer, N. Supportive care in multiple myeloma. Best Practice & Research. Clinical Haematology. 2007;20(4):817-835.Rajkumar, S.V. Multiple Myeloma: 2018 update on Diagnosis, Risk-stratification and Management. American journal of hematology. 2018;93(8):981-1114.Rajkumar, S.V. Multiple Myeloma: 2018 update on Diagnosis, Risk-stratification and Management. American journal of hematology. 2018;93(8):981-1114.Fernandez-Ruiz, M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(2):S2-S9.Fernandez-Ruiz, M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(2):S2-S9.Stoma, I., et al. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. Vaccine. 2020;38(30):4713-4716.Stoma, I., et al. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. Vaccine. 2020;38(30):4713-4716.Mustafa, SS, et al. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Human Vaccines & Immunotherapeutics. 2019;15(2):452-454.Mustafa, SS, et al. Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls. Human Vaccines & Immunotherapeutics. 2019;15(2):452-454.Renaud, L, et al. Response to pneumococcal vaccination in multiple myeloma, Cancer Medicine. 2019;8(8):3822-3830.Renaud, L, et al. Response to pneumococcal vaccination in multiple myeloma, Cancer Medicine. 2019;8(8):3822-3830.Pasiarski, M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance -relationship with selected immune and clinical parameters. Clinical Interventions in Aging. 2019;14:1741-1749.Pasiarski, M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance -relationship with selected immune and clinical parameters. Clinical Interventions in Aging. 2019;14:1741-1749.Babel, N, et al. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplantation Proceedings. 2004;36(9):2679-2682.Babel, N, et al. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplantation Proceedings. 2004;36(9):2679-2682.Tete, SM, et al. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Frontiers in Immunology. 2014;5:257.Tete, SM, et al. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Frontiers in Immunology. 2014;5:257.Blade, J, et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22(9):1651-1657.Blade, J, et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22(9):1651-1657.Kyle, RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2006;354(13):1362-1369.Kyle, RA, et al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2006;354(13):1362-1369.Kristinsson, SY, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854-858.Kristinsson, SY, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854-858.Rajkumar, SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. 2014;15(12):E538-548.Rajkumar, SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology. 2014;15(12):E538-548.Kyle, RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine. 2007;356(25):2582-2590.Kyle, RA, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. The New England Journal of Medicine. 2007;356(25):2582-2590.Bahuaud, M, et al. Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon. 2017;3(11):E00441.Bahuaud, M, et al. Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon. 2017;3(11):E00441.Lode, H, et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. Vaccine. 2011;29(31):4940-4946.Lode, H, et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. Vaccine. 2011;29(31):4940-4946.Thompson, MA, et al. Multiple myeloma baseline immunoglobulin g level and pneumococcal vaccination antibody response. Journal of Patient-Centered Research and Reviews. 2017;4(3):131-135.Thompson, MA, et al. Multiple myeloma baseline immunoglobulin g level and pneumococcal vaccination antibody response. Journal of Patient-Centered Research and Reviews. 2017;4(3):131-135.Beers, SA, Glennie, MJ, White, AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097-1101.Beers, SA, Glennie, MJ, White, AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097-1101.Karlsson, J, et al. Poor correlation between pneumococcal igg and igm titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and waldenstrom's macroglobulinemia. Clinical and Vaccine Immunology : CVI. 2016;2(4):379-385.Karlsson, J, et al. Poor correlation between pneumococcal igg and igm titers and opsonophagocytic activity in vaccinated patients with multiple myeloma and waldenstrom's macroglobulinemia. Clinical and Vaccine Immunology : CVI. 2016;2(4):379-385.Hinge, M, et al. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2012;120(11):935-940.Hinge, M, et al. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2012;120(11):935-940.

The authors declare that there are no conflicts of interest present.